Resource Summary Report

Generated by dkNET on Sep 6, 2026

Non-phospho (Active) ?-Catenin (Ser33/37/Thr41) (D13A1) Rabbit mAb

RRID:AB_11127203
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 8814, RRID:AB_11127203

Antibody Information

URL: http://antibodyregistry.org/AB_11127203

Proper Citation: Cell Signaling Technology Cat# 8814, RRID:AB_11127203

Target Antigen: Non-phospho (Active) ?-Catenin (Ser33/37/Thr41) (D13A1) Rabbit mAb

Clonality: unknown

Comments: Applications: W, IP, IHC-P, IF-IC, F, ChIP, ChIP-seq

Antibody Name: Non-phospho (Active) ?-Catenin (Ser33/37/Thr41) (D13A1) Rabbit mAb

Description: This unknown targets Non-phospho (Active) ?-Catenin (Ser33/37/Thr41) (D13A1) Rabbit mAb

Target Organism: b, c, dg, rat, porcine, h, gp, canine, hr, m, horse, mouse, r, zebrafishfish, pg, x, bovine, z, human, mk

Antibody ID: AB_11127203

Vendor: Cell Signaling Technology

Catalog Number: 8814

Record Creation Time: 20231110T060820+0000

Record Last Update: 20260829T005933+0000

Ratings and Alerts

No rating or validation information has been found for Non-phospho (Active) ?-Catenin (Ser33/37/Thr41) (D13A1) Rabbit mAb.

No alerts have been found for Non-phospho (Active) ?-Catenin (Ser33/37/Thr41) (D13A1) Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 104 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Kwon YJ, et al. (2026) Basroparib inhibits YAP-driven cancers by stabilizing angiomotin. Molecular oncology, 20(5), 1284.

Fischer S, et al. (2026) Loss of ADAMTS9 disrupts ciliogenesis and collagen homeostasis resulting in Nephronophthisis-like polycystic kidneys. bioRxiv : the preprint server for biology.

Hernández-Martínez R, et al. (2026) AXIN1 and AXIN2 regulate the WNT-signaling landscape to promote distinct mesoderm programs. Developmental cell, 61(7), 1572.

Ji F, et al. (2026) Compartmentalized branched-chain amino acid metabolism orchestrates colorectal cancer dissemination via an UMP-vimentin axis. Cell metabolism, 38(4), 794.

Centonze A, et al. (2026) A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer. Cancer discovery, 16(2), 320.

Shao YY, et al. (2025) Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma. Biology direct, 20(1), 49.

Tiburcio PDB, et al. (2025) PD-L1 Expression is Mediated by microRNA Processing, Wnt/?-Catenin Signaling, and Chemotherapy in Wilms Tumor. Pediatric blood & cancer, 72(9), e31852.

High PC, et al. (2025) Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. bioRxiv : the preprint server for biology.

High PC, et al. (2025) Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models. Cell reports. Medicine, 102363.

Wang JM, et al. (2025) KIF26B promotes bladder cancer progression via activating Wnt/?-catenin signaling in a TRAF2-dependent pathway. Cell reports, 44(5), 115595.

Saikia M, et al. (2025) Blocking the functional domain of cancer cell surface TIP1 upregulates Midkine via the ?-catenin/Wnt signaling pathway. Cancer gene therapy, 32(7), 785.

Hsu YC, et al. (2025) Overexpression of NR1D1 Portends Disease Recurrence in Thyroid Cancer. The Journal of clinical endocrinology and metabolism, 110(4), 991.

Diegel CR, et al. (2025) The class A repeats of LRP5 are required for normal development of bone, retinal vasculature and mammary gland in vivo. Disease models & mechanisms, 18(11).

Hua S, et al. (2025) Genetic disruption of the circadian gene Bmal1 in the intestinal epithelium reduces colonic inflammation. EMBO reports, 26(12), 3138.

Puleo N, et al. (2025) Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer. Molecular cancer therapeutics, 24(4), 639.

Mosialou I, et al. (2025) A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies. Cancer cell, 43(6), 1007.

Rozalén C, et al. (2025) TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak. Cancer cell, 43(8), 1549.

Chen MY, et al. (2025) BAG2 releases SAMD4B upon sensing of arginine deficiency to promote tumor cell survival. Molecular cell, 85(13), 2581.

Wu S, et al. (2025) Merlin controls limb development and thumb formation by regulating primary cilium-hedgehog signaling. Cell reports, 44(6), 115849.

Liu M, et al. (2025) Phosphatase PP2A is Required for CNS Myelination via Proteasome-Dependent Regulation of Sox10 Expression. Glia.